Survival in primary pulmonary hypertension: The impact of epoprostenol therapy

Circulation

Volumn 106, Issue 12, 2002, Pages 1477-1482

  McLaughlin, Vallerie V ^a   Shillington, Alicia ^a   Rich, Stuart ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Prostaglandins; Pulmonary heart disease; Survival

Indexed keywords

ADENOSINE; PROSTACYCLIN;

ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; DRUG RESPONSE; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; VASODILATATION; VITAL STATISTICS;

ADULT; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037126044     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000029100.82385.58     Document Type: Article

References (13)

1. Primary pulmonary hypertension: A national prospective study
2. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
3. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
4. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
5. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
6. Survival in primary pulmonary hypertension: Validation of a prognostic equation
7. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: Lack of benefit compared to placebo
8. Effect of oral milrinone on mortality in severe chronic heart failure
9. Effects of vesnarinone on morbidity and mortality in patients with heart failure
10. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
11. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human artery
12. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease
13. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects